title: A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of aripiprazole and perospirone in Japanese patients with schizophrenia.
  
  
  METHODS
  In this 12-week, randomized, flexible-dose, open-label study, patients diagnosed with schizophrenia were randomized to receive aripiprazole (3-30 mg/day, n=49) or perospirone (8-48 mg/day, n=51). Efficacy and safety were evaluated using the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impression-Severity Scale (CGI-S), the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) and the Barnes Akathisia Rating Scale (BAS) before treatment and every 4 weeks after the initiation of treatment.
  
  
  RESULTS
  Fifty-eight patients completed this study (aripiprazole, n=31; perospirone, n=27). No significant differences in gender, episode, age, schizophrenia type, weight, previous treatment and PANSS score were observed between the two groups at baseline. Both groups showed significant improvements during the study, with reductions in the total PANSS scores (Repeated measure analysis of variance, both p<0.0001). There were no significant differences in the PANSS change scores, CGI-S change scores, DIEPSS total score, BAS total score or over time between groups. The most common adverse event was insomnia in both groups.
  
  
  CONCLUSIONS
  In Japanese schizophrenia patients, aripiprazole and perospirone showed equal efficacy, tolerability and patient compliance. Both drugs showed good efficacy for treating schizophrenia. This paper is the first randomized study to evaluate the comparative efficacy and safety of aripiprazole and perospirone in the treatment of patients with schizophrenia.
authors.affiliation: Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan. takekity@takii.kmu.ac.jp
authors.forename: Yoshiteru
authors.initials: Y
authors.lastname: Takekita
authors.forename: Masaki
authors.initials: M
authors.lastname: Kato
authors.forename: Masataka
authors.initials: M
authors.lastname: Wakeno
authors.forename: Shiho
authors.initials: S
authors.lastname: Sakai
authors.forename: Azusa
authors.initials: A
authors.lastname: Suwa
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Nishida
authors.forename: Gaku
authors.initials: G
authors.lastname: Okugawa
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Kinoshita
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000068180:Aripiprazole; D005260:Female; D006801:Humans; D054833:Isoindoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007564:Japan; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015363:Quinolones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D012720:Severity of Illness Index; D013844:Thiazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D054833:Isoindoles; D010879:Piperazines; D015363:Quinolones; D013844:Thiazoles; D000068180:Aripiprazole; C065533:perospirone